TriangleAnti-GARP Chimeric Antigen Receptor… (NCT06964737)
Anti-GARP Chimeric Antigen Receptor T Cel… trial for Recurrent Malignant Glioma (NCT06964737). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
When a high-grade glioma returns after standard treatment, there is no agreed next step. And the tumor walls itself off, releasing a signal, TGF-beta, that tells immune cells to stand down.
The idea: go after the protein that holds that signal on the cell surface.
It is called GARP; tumors with a lot of it do worse. A patient's own T cells are fitted with a receptor for it. At surgery, a small reservoir is placed under the scalp, and over five weeks the cells go straight into the cavity the tumor left.
In mice, the cells worked against several glioblastoma models without serious harm. This trial, at Ohio State with Brad Elder, asks first whether it is safe. Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.